Homepage > Company > Media > Pharma News > 2016 > Pfizer to Buy Anacor for $4.5 Billion

Pfizer to Buy Anacor for $4.5 Billion

Pfizer Inc. said Monday it would buy Anacor Pharmaceuticals Inc. in an all-cash deal worth about $4.5 billion, as it turns to smaller deals after walking away from its scuttled acquisition of Allergan PLC.

Pfizer PFE, +0.57% will acquire drugmaker Anacor ANAC, +57.22% for $99.25 a share, a 55% premium to Friday’s closing price. The companies said the deal, including debt, is valued at $5.2 billion.

On Monday, the companies said Palo Alto-based Anacor will be a “strong fit” with New York-based Pfizer’s inflammation and immunology portfolio. Anacor has no products on the market, but its flagship asset, crisaborole, is currently under review by the U.S. Food and Drug Administration for the treatment of eczema.

Pfizer said the transaction, which is expected to close in the third quarter, will not impact its guidance for the year.

Published: May 16, 2016

Source: http://www.marketwatch.com/

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)